Bavarian Nordic A/S (BVNRY)
USD 7.57
(-0.66%)
USD 7.57
(-0.66%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.47 Billion DKK | 524.66% |
| 2022 | -347.38 Million DKK | 25.26% |
| 2021 | -464.77 Million DKK | -267.47% |
| 2020 | 277.52 Million DKK | 180.03% |
| 2019 | -346.77 Million DKK | 4.19% |
| 2018 | -361.92 Million DKK | -299.58% |
| 2017 | 181.34 Million DKK | 492.62% |
| 2016 | 30.6 Million DKK | -48.51% |
| 2015 | 59.42 Million DKK | 129.09% |
| 2014 | 25.94 Million DKK | 155.51% |
| 2013 | -46.72 Million DKK | 80.53% |
| 2012 | -240 Million DKK | 10.59% |
| 2011 | -268.42 Million DKK | 31.16% |
| 2010 | -389.91 Million DKK | -46.43% |
| 2009 | -266.27 Million DKK | -77.1% |
| 2008 | -150.35 Million DKK | -150.71% |
| 2007 | -59.97 Million DKK | 62.05% |
| 2006 | -158.04 Million DKK | -66.83% |
| 2005 | -94.73 Million DKK | -78.69% |
| 2004 | -53.01 Million DKK | -135.21% |
| 2003 | 150.56 Million DKK | 114.72% |
| 2002 | 70.12 Million DKK | 176.15% |
| 2001 | -92.08 Million DKK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 261.12 Million DKK | 328.16% |
| 2024 Q1 | -114.45 Million DKK | -112.7% |
| 2023 FY | 1.47 Billion DKK | 524.66% |
| 2023 Q4 | 901.39 Million DKK | 364.61% |
| 2023 Q1 | 376.36 Million DKK | 151.54% |
| 2023 Q3 | -340.64 Million DKK | -163.31% |
| 2023 Q2 | 538.07 Million DKK | 42.97% |
| 2022 Q3 | 12.1 Million DKK | 105.11% |
| 2022 Q4 | 149.62 Million DKK | 1135.74% |
| 2022 Q1 | -271.94 Million DKK | -166.01% |
| 2022 Q2 | -237.17 Million DKK | 12.79% |
| 2022 FY | -347.38 Million DKK | 25.26% |
| 2021 Q1 | -130.84 Million DKK | 65.08% |
| 2021 Q3 | -81.44 Million DKK | 45.8% |
| 2021 FY | -464.77 Million DKK | -267.47% |
| 2021 Q4 | -102.23 Million DKK | -25.53% |
| 2021 Q2 | -150.25 Million DKK | -14.84% |
| 2020 Q2 | 111.27 Million DKK | -78.38% |
| 2020 Q1 | 514.57 Million DKK | 1221.35% |
| 2020 Q4 | -374.68 Million DKK | -1521.99% |
| 2020 FY | 277.52 Million DKK | 180.03% |
| 2020 Q3 | 26.34 Million DKK | -76.32% |
| 2019 Q4 | -45.88 Million DKK | 53.73% |
| 2019 Q1 | -99.62 Million DKK | 1.74% |
| 2019 Q2 | -102.08 Million DKK | -2.47% |
| 2019 FY | -346.77 Million DKK | 4.19% |
| 2019 Q3 | -99.18 Million DKK | 2.84% |
| 2018 Q2 | -109.81 Million DKK | 39.81% |
| 2018 Q4 | -101.38 Million DKK | -419.64% |
| 2018 Q1 | -182.44 Million DKK | 1.15% |
| 2018 FY | -361.92 Million DKK | -299.58% |
| 2018 Q3 | 31.71 Million DKK | 128.88% |
| 2017 Q3 | 325.67 Million DKK | 603.5% |
| 2017 Q4 | -184.57 Million DKK | -156.67% |
| 2017 FY | 181.34 Million DKK | 492.62% |
| 2017 Q1 | -6.05 Million DKK | -106.93% |
| 2017 Q2 | 46.29 Million DKK | 865.05% |
| 2016 Q1 | -128.75 Million DKK | -5661.68% |
| 2016 Q2 | -25.78 Million DKK | 79.98% |
| 2016 FY | 30.6 Million DKK | -48.51% |
| 2016 Q3 | 97.81 Million DKK | 479.4% |
| 2016 Q4 | 87.31 Million DKK | -10.74% |
| 2015 FY | 59.42 Million DKK | 129.09% |
| 2015 Q4 | 2.31 Million DKK | 104.66% |
| 2015 Q3 | -49.62 Million DKK | -180.88% |
| 2015 Q2 | 61.36 Million DKK | 35.23% |
| 2015 Q1 | 45.37 Million DKK | -53.67% |
| 2014 Q3 | -18.3 Million DKK | 66.67% |
| 2014 Q4 | 97.94 Million DKK | 635.19% |
| 2014 FY | 25.94 Million DKK | 155.51% |
| 2014 Q1 | 1.2 Million DKK | 104.47% |
| 2014 Q2 | -54.9 Million DKK | -4675.0% |
| 2013 Q2 | -5.3 Million DKK | 84.32% |
| 2013 Q3 | 19.2 Million DKK | 462.26% |
| 2013 Q4 | -26.82 Million DKK | -239.73% |
| 2013 FY | -46.72 Million DKK | 80.53% |
| 2013 Q1 | -33.8 Million DKK | 45.57% |
| 2012 Q3 | 19.8 Million DKK | 111.76% |
| 2012 Q2 | -168.4 Million DKK | -474.74% |
| 2012 Q4 | -62.1 Million DKK | -413.64% |
| 2012 FY | -240 Million DKK | 10.59% |
| 2012 Q1 | -29.3 Million DKK | -453.91% |
| 2011 Q4 | 8.27 Million DKK | 116.49% |
| 2011 Q3 | -50.2 Million DKK | 57.35% |
| 2011 FY | -268.42 Million DKK | 31.16% |
| 2011 Q2 | -117.7 Million DKK | -8.18% |
| 2011 Q1 | -108.8 Million DKK | -39.29% |
| 2010 Q3 | -163.7 Million DKK | -195.49% |
| 2010 FY | -389.91 Million DKK | -46.43% |
| 2010 Q4 | -78.11 Million DKK | 52.28% |
| 2010 Q2 | -55.4 Million DKK | 40.37% |
| 2010 Q1 | -92.9 Million DKK | -71.47% |
| 2009 Q3 | -63 Million DKK | 23.91% |
| 2009 Q4 | -54.17 Million DKK | 14.0% |
| 2009 FY | -266.27 Million DKK | -77.1% |
| 2009 Q2 | -82.8 Million DKK | -24.89% |
| 2009 Q1 | -66.3 Million DKK | 0.0% |
| 2008 FY | -150.35 Million DKK | -150.71% |
| 2007 FY | -59.97 Million DKK | 62.05% |
| 2006 FY | -158.04 Million DKK | -66.83% |
| 2005 FY | -94.73 Million DKK | -78.69% |
| 2004 FY | -53.01 Million DKK | -135.21% |
| 2003 FY | 150.56 Million DKK | 114.72% |
| 2002 FY | 70.12 Million DKK | 176.15% |
| 2001 FY | -92.08 Million DKK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Capstone Therapeutics Corp. | -3.81 Million USD | 38727.625% |
| Skye Bioscience, Inc. | -37.64 Million USD | 4018.708% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | -2164.89% |
| Nascent Biotech, Inc. | -2.08 Million USD | 70761.576% |
| Qrons Inc. | -789.34 Thousand USD | 186987.263% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | -8.48 Million USD | 17489.977% |
| CSL Limited | 2.64 Billion USD | 44.164% |
| Evofem Biosciences, Inc. | 52.97 Million USD | -2684.479% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 21225.929% |
| Regen BioPharma, Inc. | 1.02 Million USD | -144030.676% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 2456.57% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 355157.416% |
| Rebus Holdings, Inc. | -1.02 Million USD | 144726.373% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | 110565.385% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 233365.761% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 9394.612% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 2067.889% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 22532.544% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 539667.743% |
| SQZ Biotechnologies Company | -79.46 Million USD | 1956.424% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 51102.353% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 81130.833% |
| Mesoblast Limited | -87.95 Million USD | 1777.19% |
| Marizyme, Inc. | -65.34 Million USD | 2357.473% |
| Genus plc | 7.9 Million USD | -18573.278% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 13644.106% |
| Pharming Group N.V. | -10.54 Million USD | 14085.485% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 68086.887% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 39859.999% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 16780.111% |
| ContraFect Corporation | -65.15 Million USD | 2364.192% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 30291.772% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 85496.667% |
| IMV Inc. | -36.48 Million USD | 4143.198% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 18403.315% |
| MultiCell Technologies, Inc. | -380.07 USD | 388136232.818% |
| ONE Bio Corp. | 8.67 Million USD | -16901.901% |
| Accustem Sciences Inc. | -3.74 Million USD | 39475.975% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 2953.805% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 116519.337% |
| Q BioMed Inc. | -2.05 Million USD | 71987.044% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 39617.519% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 62060.082% |
| Biomind Labs Inc. | -1.21 Million USD | 121582.823% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 2569.953% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 47659.618% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 18765.97% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 75779.864% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 9850453.9% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 25458.859% |
| GB Sciences, Inc. | -1.36 Million USD | 108436.191% |
| Alpha Cognition Inc. | -13.77 Million USD | 10811.068% |
| HST Global, Inc. | -146.21 Thousand USD | 1009052.192% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 84167.323% |
| Halberd Corporation | -79.67 Thousand USD | 1851584.763% |
| Enzolytics Inc. | -2.17 Million USD | 67867.701% |
| Agentix Corp. | -1.37 Million USD | 107448.071% |
| Resverlogix Corp. | -3.61 Million USD | 40963.961% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 46614.86% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 599.974% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -1505194.898% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | -21203.617% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 37230.42% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 48848.288% |
| AVAX Technologies, Inc. | -6.41 Million USD | 23100.779% |
| Zenith Capital Corp. | -10.59 Million USD | 14022.131% |
| Genscript Biotech Corporation | -95.47 Million USD | 1645.073% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 6347182.867% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 35681.567% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 2440824.87% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 73671.291% |
| Kadimastem Ltd | -3.3 Million USD | 44702.706% |
| Helix BioMedix, Inc. | -1.05 Million USD | 139788.388% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 334330.315% |
| LadRx Corporation | 400.44 Thousand USD | -368289.259% |
| Cell Source, Inc. | -5.32 Million USD | 27822.801% |
| Regen BioPharma, Inc. | 1.02 Million USD | -144030.676% |
| NovAccess Global Inc. | -4.76 Million USD | 31031.666% |
| Affymax, Inc. | -14.42 Million USD | 10327.323% |
| Itoco Inc. | -1.86 Million USD | 79029.532% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 33306.019% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 88487.597% |
| Mobile Lads Corp. | -2.26 Million USD | 65278.908% |
| CytoDyn Inc. | -49.84 Million USD | 3059.79% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 1866648.151% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 646752.522% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 156780.145% |
| SYBLEU INC | -180.3 Thousand USD | 818267.65% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 91571.145% |
| International Stem Cell Corporation | -131 Thousand USD | 1126198.473% |
| Bioxytran, Inc. | -4.28 Million USD | 34567.017% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 2718240.109% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 58402.174% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 3168.707% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 69881.883% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 189011.968% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 46665.309% |
| Neutra Corp. | -233.46 Thousand USD | 631967.303% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 7370.164% |
| PureTech Health plc | -65.69 Million USD | 2345.443% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 7036.668% |
| IXICO plc | -1.17 Million USD | 125328.268% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 14960.371% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 2682.252% |
| CSL Limited | 2.64 Billion USD | 44.164% |
| Cellectis S.A. | -103.17 Million USD | 1529.809% |